Results 221 to 228 of about 10,879 (228)

Ledipasvir‐Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C

Hepatology, 2020
Philip Rosenthal, Jonathan R Honegger, Winita Hardikar   +2 more
exaly  

Real‐world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment‐naive, genotype 1 hepatitis C‐infected patients

Hepatology, 2016
Pamela Belperio
exaly  

Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt

Gut, 2019
Gamal E Shiha, Gamal Esmat, Mohamed Hassany   +2 more
exaly  

Treatment with ledipasvir and sofosbuvir improves patient‐reported outcomes: Results from the ION‐1, ‐2, and ‐3 clinical trials

Hepatology, 2015
Zobair M Younossi, Maria Stepanova, Nezam Afdhal   +2 more
exaly  

Favouring modulation of circulating lipoproteins and lipid loading capacity by direct antiviral agents grazoprevir/elbasvir or ledipasvir/sofosbuvir treatment against chronic HCV infection

Gut, 2018
Pin-Nan Cheng, Kung-Chia Young
exaly  

A facile synthesis of 3D NiFe2O4 nanospheres anchored on a novel ionic liquid modified reduced graphene oxide for electrochemical sensing of ledipasvir: Application to human pharmacokinetic study

Biosensors and Bioelectronics, 2018
Mohamed M El-Wekil, Ashraf M Mahmoud, Saad A Alkahtani   +2 more
exaly  

Faculty Opinions recommendation of Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: A Randomized Trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature, 2019
J. Francis
semanticscholar   +1 more source

Discovery of Ledipasvir (GS-5885): A Potent, Once-Daily Oral NS5A Inhibitor for the Treatment of Hepatitis C Virus Infection

Journal of Medicinal Chemistry, 2014
exaly